<!doctype html>
  <html>
    <head>
<meta charset="utf-8">
<title>Scan To Cu-Re </title>
<link href="Cure Decor.css" rel="stylesheet">
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@5.15.4/css/fontawesome.min.css" integrity="sha384-jLKHWM3JRmfMU0A5x5AkjWkw/EYfGUAGagvnfryNV3F9VqM98XiIH7VBGVoxVSc7" crossorigin="anonymous">
    </head>

    <header>
      <div class="navi">
        <p><a href="index.html">Scan to Cure</a></p>
        <ul>
          <li><a href="Structure.html">Genomic Characteritics of Corona Virus</a></li>
            <ul>
            </ul>
          </li>
            
          <li class="pob"><a href="#">General Info of COVID Pro-Drugs</a>
            <ul class="bop">
              <li><a href="Remdesivier Abstract.html">Remdesivir</a></li>
              <li><a href="Fluvoxamine Abstract.html">Fluvoxamine</a></li>
              <li><a href="Molnupiravir Abstract.html">Molnupiravir</a></li>
            </ul>
          </li>
          <li class="pob"><a href="#">Mechanism of Action</a>
            <ul class="bop">
              <li><a href='Remdesivier.html'>Remdesivir</a></li>
              <li><a href='Fluvoxamine.html'>Fluvoxamine</a></li>
              <li><a href='Molnupiravir.html'>Molnupiravir</a></li>
            </ul>
          </li>
          <li class="no-drop"><a href='Similarities & Differences.html'>Similarities & Differences</a></li>
            <li class="no-drop"><a href='Literature Sources.html'>Literature Source</a></li>
        </ul>
      </div>
      <div class="menu-toggle">
        <i class="fas fa-bars" aria-hidden="true"></i>
      </div>
      <div class="menu">
      <div class="menu-line"></div>
      <div class="menu-line"></div>
      <div class="menu-line"></div>
    </div>
    </header>

<body>
  <div class = "for">
    <h2>Molnupiravir</h2>
    <h4>Abstract</h4>
    <br>
    <p>Molnupiravir is an isopropylester prodrug of the nucleoside analog β-D-N4- hydroxycytidine (NHC or EIDD-1931). Molnupiravir interferes with the replication of  various viruses, including SARS-CoV-2. It inhibits SARS-CoV-2 replication in human lung  tissue, blocks SARS-CoV-2 transmission in ferrets and reduces SARS-CoV-2 RNA in  patients. In contrast to approved drugs such as remdesivir that are administered by infusion,  molnupiravir is orally available. Molnupiravir has been tested in phase I trial for safety,  tolerability and pharmacokinetics, and phase II/III studies are currently ongoing  (NCT04405739, NCT04405570 and NCT04575597). Available data suggest that  molnupiravir acts as a mutagenizing agent that causes an ‘error catastrophe’ during viral  replication. Indeed, NHC can introduce mutations into viral RNA, as shown for Venezuelan  equine encephalitis virus. Also, the sequencing of influenza virus populations has indicated  that NHC causes G-to-A and C-to-U transitions in viral RNA, and the same transitions have  been found for SARS-CoV-2. 
    </p>
    <p><img src="https://media.npr.org/assets/img/2021/11/30/merck_pill2-1-4feb79f12ce4cd2015ad641582f8dfefdccd2d46-s1100-c50.jpg" height="600" width="700"></p>
    <p><img src="https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcRBEGdfuHyMV09tE96p_FebLi5DYJS55-IchCsENOhICNHTOsMwLaygb4NgRUSntONU2vQ:https://www.science.org/do/10.1126/blog-post.16987/full/molnupiravir.png&usqp=CAU" height="600" width="700"></p>
  </div>
    </body>
    </html>